The prescribing information includes a boxed warning stating<unk>  causes changes in the corneal epithelium resulting in alterations in vision, including severe vision loss and corneal ulcer, and symptoms, such as blurred vision and dry eyes. Because of the risks of ocular toxicity,<unk>  is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS), called the BLENREP REMS.
Belantamab mafodotin
Brexucabtagene autoleucel
Ciltacabtagene autoleucel
Enadenotucirev
Baloxavir marboxil
Idecabtagene vicleucel
Trenbolone hexahydrobenzylcarbonate
Valoctocogene roxaparvovec